乳腺癌组织HER-2/neu基因扩增和蛋白表达及其临床意义的研究

Detection and clinical significance of HER-2/neu protein expression and gene amplification in breast cancer

目的:对比研究乳腺癌中免疫组化检测c-erbB-2蛋白表达和显色原位杂交法(CISH)检测HER-2基因扩增,并评估其临床应用价值。方法:免疫组化Elivision法及CISH法分别检测69例乳腺癌组织中c-erbB-2蛋白表达及HER-2基因DNA扩增状况,并进行对比分析。结果:69例乳腺癌中c-erbB-2蛋白阳性表达53例(76.81%),阴性表达16例(23.19%);69例乳腺癌中有32例(46.38%)出现c-erbB-2基因扩增,37例(53.62%)无扩增。22例c-erbB-2蛋白表达弱阳性和阴性者,HER-2基因均无扩增。两种方法的检测结果差异有统计学意义,P<0.05。结论:免疫组化检测可以作为临床化疗是否应用赫赛汀(Herceptin)的初筛,免疫组化呈中和强阳性的病例有必要进一步进行HER-2基因扩增的检测,来确定临床化疗是否应用Herceptin。

OBJECTIVE： To investigate in contrast c-erbl3-2 protein expression by immunohistochemistry and HER-2 gene amplification by chromogenic in situ hybridization in breast cancer, and to evaluate their value in clinical application. METHODS： Elivision immunohistochemistry and chromogenic in situ hybridization were used to detect c-erbB-2 protein expression and HER-2 gene amplification in 69 cases of breast cancer, respectively. RESULTS： Of 69 cases of breasr cancer, 53 cases （76.81%） were positive in expression of c-erbl3-2 protein, and 16 cases（23.19%） were negative. Thirty-two cases （46.38%） showed HER-2 gene amplification, and there was no gene amplification in the other 37 cases （53.62%） of breast cancer. In 22 cases that were displayed weakly positive or negative expression, there was no gene amplification. The difference was existed between the results of the two methods. CONCLUSIONS：The immunohistochemistry can be used to initial screening of whether or not select Herceptin in clinical therapy. The cases of c-erbl3-2 positive expression should be further detected the status of HER-2 gene amplication by CISH to determine clinical application of Herceptin.